Blog

Blog

By Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
It takes an average of 17 years to bring a scientific discovery into clinical practice. This statistic, which has been validated by research published in Public Health Reports and the Journal of the Royal Society of Medicine, reveals a troubling reality for many patients in desperate need of the new practices, tests, drugs and technologies stuck in the years-long gap between research and implementation into healthcare practices and policies. 
By Dr. Andreas Jeromin, Ph.D., Chief Medical Officer (Consulting), Quanterix

When we think of the letters N-F-L, our minds are drawn to football and the National Football League. However, NfL, or ineurofilament light chain as the non-abbreviated name, is also a powerful protein that has shown promise for the early detection and diagnosis of brain injuries, as well as several neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.

By Kevin Hrusovsky, Executive Chairman and CEO, Quanterix

We are privileged to live in a society that values science, technology, engineering and mathematics. Better known as STEM, these programs play a critical role in the advancement of our society, and are shaping the future of medicine and other disciplines. STEM makes it possible for our children to live in a world where diseases can be detected before symptoms are present and developing nations can implement sustainable initiatives to end poverty.

By Kevin Hrusovsky, EXECUTIVE CHAIRMAN AND CEO, QUANTERIX
As a company that believes we have the power to improve player safety, we also know that change cannot happen unless we have unified support from the entire community, including researchers, scientists, doctors, patients, patient advocates, investors, and institutions like the NFL.
By Dr. Mark Roskey and Dr. David Duffy

We were honored to be able to speak about the promise of immuno-oncology (IO) therapeutics at this year’s Molecular Med Tri-Con conference and the 12th Annual Biomarkers Congress. Bringing together thought leaders from around the world, including academics, pharma customers and therapeutic companies, these conferences are critical for the acceleration of precision health for improved treatment methods across a variety of disease-types.